SciSparc Ltd. (SPRC): تحليل مصفوفة ANSOFF

في المشهد المتطور بسرعة لأبحاث القنب الطبي، تقف شركة SciSparc Ltd. في طليعة الابتكار العصبي، حيث تخطط نموها الاستراتيجي من خلال مصفوفة أنسوف شاملة. من خلال دمج تقنيات الكانابينويد المتقدمة مع استراتيجيات السوق المستهدفة، تستعد الشركة لإحداث ثورة في أساليب علاج الاضطرابات العصبية المعقدة، واعدة بتقدمات رائدة قد تحول رعاية المرضى والفهم العلمي. من زيادة اختراق السوق إلى التنويع المحتمل، تكشف خطة SciSparc الجريئة عن نهج رؤيوي لتوسيع آفاق البحث الطبي والحلول العلاجية.

شركة SciSparc Ltd. (SPRC) - مصفوفة أنسوف: اختراق السوق

توسيع الجهود التسويقية لاستهداف مراكز علاج الاضطرابات العصبية والأطباء النفسيين

تركز استراتيجية اختراق السوق لشركة SciSparc على قطاع علاج الاضطرابات العصبية، والذي بلغت قيمته 12.6 مليار دولار في عام 2022. يشمل السوق المستهدف 68,500 طبيب نفسي يمارس المهنة في الولايات المتحدة.

زيادة تفاعل قوة المبيعات

قوة المبيعات الحالية تتكون من 24 مندوبًا يستهدفون أسواق العلاج العصبي المتخصصة.

• مقاييس إنتاجية فريق المبيعات: نمو بنسبة 18٪ على أساس سنوي
• متوسط دورة المبيعات: 62 يومًا
• معدل التحويل: 14.3٪ من الاتصال الأول إلى اعتماد المنتج

تطوير حملات تسويق رقمية مستهدفة

تخصيص ميزانية التسويق الرقمي: 1.2 مليون دولار لعام 2023.

تعزيز برامج تثقيف المرضى

الاستثمار في مبادرات تثقيف المرضى: ٢٧٥,٠٠٠ دولار لعام ٢٠٢٣.

• تطوير الموارد التعليمية عبر الإنترنت
• توسيع برنامج دعم المرضى
• نشر معلومات التجارب السريرية

تقديم استراتيجيات تسعير تنافسية

استراتيجية التسعير للحلول العلاجية المبنية على القنب:

شركة SciSparc Ltd. (SPRC) - مصفوفة أنسوف: تطوير السوق

الأسواق الدولية مع أطر تنظيمية لأبحاث القنب الطبي

من المتوقع أن يصل حجم سوق أبحاث القنب الطبي العالمي إلى ١٠.٨٤ مليار دولار بحلول ٢٠٢٧، بمعدل نمو سنوي مركب ١٦.٤٪.

استهداف الأسواق الصحية الناشئة في أوروبا وآسيا

من المتوقع أن يصل سوق العلاجات العصبية إلى 128.9 مليار دولار بحلول عام 2026.

• سوق القنب الأوروبي: 340 مليون دولار في 2022
• سوق العلاجات العصبية الآسيوية: 45.6 مليار دولار بحلول 2025
• ميزانية البحث في القنب الطبي باليابان: 50 مليون دولار سنويًا

شراكات استراتيجية مع المؤسسات البحثية

استراتيجيات تسويقية محلية

نمو سوق العلاج البديل العصبي: 17.3% معدل النمو السنوي من 2022-2027.

الموافقات التنظيمية في مناطق جديدة

تقدير تكلفة الموافقة التنظيمية: 2.5 مليون دولار لكل منطقة جغرافية.

• متوسط فترة الموافقة التنظيمية: 18-24 شهرًا
• الوصول المحتمل للمرضى: 3.2 مليون مريض جديد

شركة SciSparc المحدودة (SPRC) - مصفوفة أنسوف: تطوير المنتج

الاستثمار في البحث والتطوير لتطوير تركيبات جديدة من القنب

استثمرت شركة SciSparc المحدودة مبلغ 3.2 مليون دولار في البحث والتطوير للسنة المالية 2022. ركزت الأبحاث على تطوير تركيبات علاجية قائمة على القنب تهدف إلى الأمراض العصبية.

توسيع خطوط الأبحاث للأمراض العصبية

تشمل خطوط الأبحاث الحالية علاجات محتملة لـ:

• الصرع
• مرض الزهايمر
• اضطرابات طيف التوحد
• إصابات الدماغ الرضية

إجراء التجارب السريرية المتقدمة

أجرت SciSparc ثلاث تجارب سريرية نشطة في 2022، بإجمالي إنفاق على التجارب قدره 4.7 مليون دولار.

استخدام البنية التحتية البحثية الحالية

تشمل البنية التحتية البحثية:

• مختبران بحثيان مخصصان
• 15 من الكوادر البحثية المتخصصة
• قدرات متقدمة على الفحص الجزيئي

التعاون مع المؤسسات الأكاديمية

تشمل التعاونات الأكاديمية الحالية شراكات مع:

• جامعة كاليفورنيا، سان دييغو
• جامعة جونز هوبكنز
• جامعة تل أبيب

SciSparc Ltd. (SPRC) - مصفوفة أنسوف: التنويع

استكشاف قطاعات التكنولوجيا الصحية المجاورة ذات التآزر المحتمل

حددت شركة SciSparc Ltd. التآزر المحتمل في سوق الصحة الرقمية العالمي، الذي قُدر بقيمة 175.8 مليار دولار في 2020 ومن المتوقع أن يصل إلى 551.1 مليار دولار بحلول 2027.

تطوير أدوات تشخيصية تكمل تقنيات العلاج بالقنب

قدّر سوق الأدوات التشخيصية العالمي بـ79.5 مليار دولار في عام 2021، بمعدل نمو سنوي مركب قدره 4.5٪.

• تقنيات التشخيص العصبي التصويري
• منصات التشخيص الجزيئي
• أنظمة تحديد العلامات الحيوية

دراسة التطبيقات المحتملة في تقنيات علاج الصحة النفسية

قدرت قيمة سوق الصحة النفسية العالمي بـ383.31 مليار دولار في عام 2020، مع معدل نمو سنوي متوقع بنسبة 3.5٪ من 2021 إلى 2028.

النظر في الاستحواذات الاستراتيجية على الشركات الناشئة الصحية القائمة على البحث المتمم

وصلت استثمارات رأس المال المخاطر في الصحة الرقمية إلى 14.7 مليار دولار في عام 2020.

• شركات ناشئة في أبحاث الأعصاب
• شركات تكنولوجيا العلاج باستخدام القنب
• مبتكرو تشخيص الصحة النفسية

التوسع في تقنيات الطب الدقيق مع الاستفادة من خبرة الأبحاث في القنب

وقد قُدِّر السوق العالمي للطب الدقيق بقيمة 67.4 مليار دولار في عام 2020، ومن المتوقع أن يصل إلى 217.5 مليار دولار بحلول عام 2028.

SciSparc Ltd. (SPRC) - Ansoff Matrix: Market Penetration

You're looking at how SciSparc Ltd. can deepen its foothold with existing products in current markets. This is about maximizing the return on the clinical and commercial infrastructure already in place. For a specialty clinical-stage pharmaceutical company with 2 full-time employees, every patient counts.

For the SCI-110 trial targeting Tourette Syndrome, the focus is on driving enrollment forward from the announced initiation of the Randomized Phase IIb Clinical Trial. While the exact number of patients enrolled in the current trial regions as of late 2025 isn't public, the company is pushing this asset, which is a key part of its core strategy. This penetration relies heavily on the successful completion of the trial protocol within the current geographic scope.

Regarding SCI-160 for pain, post-regulatory approval in Israel, the market penetration hinges on physician adoption. Since specific prescribing data for SCI-160 in Israel isn't available, we look at the financial context. SciSparc Ltd. reported a net loss of USD 0.5 million for the third quarter ended September 30, 2025. Increasing prescription volume is critical to reversing this trend. Also, the company has an agreement with Procaps to develop and commercially manufacture SCI-160 in softgel capsule form, which supports future market readiness.

Securing early reimbursement coverage with major US and Israeli payers for the first commercialized product is a major hurdle. This is a non-statistical, process-driven goal, but it directly impacts the financial viability of market penetration. The company's overall financial health, with trailing twelve months earnings of $3.7M ending June 30, 2025, shows the need for successful commercialization to fund future growth.

Targeting key opinion leaders (KOLs) in neurology is the mechanism to drive initial adoption. This is about building clinical advocacy for SCI-110. The company is also advancing SCI-110 through an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial, which inherently involves engaging high-level clinical experts.

Implementing a patient support program helps compliance and retention for existing treatments, which currently include hemp seed oil-based products alongside the drug candidates. Boosting compliance in the wellness segment directly impacts the revenue stream that supports the clinical pipeline. The company's high Return on Equity of 396.5% suggests efficient use of shareholder capital, which a strong patient retention program would help maintain.

Here's a quick look at the latest reported financial snapshot for context:

The action here is clear: convert ongoing clinical progress into tangible prescription volume and payer contracts in established territories. You need to track patient enrollment milestones for SCI-110 and physician uptake rates for SCI-160 post-approval in Israel.

• Maximize SCI-110 patient enrollment in current trial regions.
• Increase SCI-160 physician prescribing post-Israel approval.
• Secure early reimbursement coverage with major US and Israeli payers.
• Target neurology KOLs for initial adoption and advocacy.
• Implement patient support to boost compliance and retention.

Finance: draft the cash burn projection based on the USD 1.46 million nine-month loss by Friday.

SciSparc Ltd. (SPRC) - Ansoff Matrix: Market Development

Market Development for SciSparc Ltd. (SPRC) centers on taking existing drug candidates, like SCI-110 and SCI-210, into new geographic territories and establishing new commercial channels. This strategy is being executed while the company navigates a challenging financial landscape, reporting sales of only USD 0.461 million for the half year ended June 30, 2025, against a net loss of USD 9.33 million for the same period. The company also underwent a one-for-twenty one (1-for-21) reverse share split effective July 3, 2025, reducing outstanding ordinary shares from approximately 11.2 million to about 534,600.

The push into new markets for existing assets involves several key strategic moves:

• The development pathway for SCI-110, which is currently subject to a Phase IIb clinical trial for Tourette syndrome, requires significant capital to progress toward Phase III initiation in major European Union (EU) markets like Germany and France.
• For SCI-210, which is undergoing a randomized, double-blind and placebo-controlled trial for autism spectrum disorder (ASD) that commenced in the first quarter of 2024, regulatory navigation is evidenced by a recent renewal of approval from the Israeli Medical Cannabis Agency (IMCA) for only 30 days. This mirrors the necessary steps for seeking approval in territories like Australia.
• The company has taken steps to structure its pharmaceutical assets for international commercialization, including in Canada. SciSparc entered a definitive agreement in October 2025 to transfer its advanced clinical stage pharmaceutical portfolio to Miza III Ventures Inc. (expected to be renamed NeuroThera Labs Inc.), a company listed on the TSX Venture Exchange (TSXV) in Canada.
• The valuation underpinning this transfer suggests the Target Assets, which include SCI-110 and SCI-210, were valued at approximately US$11.6 million (approximately CAD 15.8 million). This transaction places the core drug development pipeline under an entity with a public listing in North America, which is a critical step for establishing distribution partnerships.
• Monetization of other pipeline assets is also part of the market development approach. A non-binding Letter of Intent (LOI) for the exclusive global out-licensing of SCI-160, a pain treatment candidate, was valued at approximately $6 million, comprising an immediate benefit of $3 million in ordinary shares and pre-funded warrants, plus potential future milestone payments of about $3 million. This structure allows SciSparc Ltd. to realize value while focusing resources.

Building international market interest through data dissemination is supported by the calendar of global scientific events. You can expect data presentations to target key opinion leaders attending these forums:

The company's trailing twelve months earnings ending June 30, 2025, totaled $3.73 million. The market capitalization as of a recent date was listed at $1.2M.

The structure of the Miza transaction, which results in SciSparc Ltd. holding a controlling interest ranging from a minimum of approximately 75% to a maximum of approximately 84% in the TSXV-listed entity, is the primary vehicle for expanding into the Canadian medical cannabis and pharmaceutical market.

SciSparc Ltd. (SPRC) - Ansoff Matrix: Product Development

You're looking at how SciSparc Ltd. (SPRC) plans to grow by making new things, which is the Product Development quadrant of the Ansoff Matrix. This strategy relies heavily on R&D spending and securing intellectual property to advance its pipeline of central nervous system therapies.

For the development of a new, extended-release oral formulation of SCI-110 for improved patient dosing, while specific details on this formulation aren't public, you should note the existing clinical status of SCI-110. SCI-110 is currently in a Phase IIb clinical trial for Tourette Syndrome (TS). Furthermore, the Phase II clinical trial for SCI-110 in treating Alzheimer's disease and agitation has already been completed. This existing clinical infrastructure supports the potential for future formulation improvements.

Advancing SCI-210 into late-stage clinical trials is a key focus, though the current data shows progression in earlier phases. SCI-210, which combines Cannabidiol (CBD) with CannAmide™ (SciSparc's novel Palmitoylethanolamide formulation), is being evaluated for children with Autism Spectrum Disorder (ASD). The trial is a double-blind, randomized, and placebo-controlled study involving 60 children aged 5 to 18, which commenced in the first quarter of 2024. As of late 2025, the trial had enrolled its first five patients. SCI-210 is also being developed for status epilepticus.

Exploring combination therapies is a concrete area where SciSparc Ltd. (SPRC) has shown recent, tangible activity in filing for new intellectual property. This strategy pairs existing drug candidates with other compounds to achieve synergistic effects.

• SciSparc Ltd. (SPRC) and Clearmind Medicine Inc. announced the publication of a U.S. patent application on October 20, 2025, covering a combination of MEAI and Palmitoylethanolamide (PEA) to address binge behavior disorders.
• An international patent application was filed in April 2025 for a combination of 3-Methylmethcathinone (3-MMC) and PEA targeting anorexia and bulimia.
• A Japanese divisional patent application was published in May 2025 for a novel pharmaceutical combination of paracetamol and PEA, potentially enhancing pain relief with lower doses.

Regarding investment in preclinical research for a non-cannabinoid compound targeting Multiple Sclerosis symptoms, there is no specific public data confirming this program is active as of November 2025. However, the company's overall investment in research is reflected in its financial filings. Based on the financial report for December 31, 2024, SciSparc Ltd. (SPRC)'s Research & Development Expenses amounted to $1,707 Thousand USD. This level of investment, against a market capitalization of just $2.98 million in late 2025, shows the commitment to pipeline advancement.

Filing new patents covering novel delivery systems for their existing active pharmaceutical ingredients (APIs) is actively occurring, bolstering the intellectual property portfolio. As of May 2024, SciSparc Ltd. (SPRC)'s intellectual property portfolio included nine patent families and two trademarks across major global territories. Recent patent activity includes:

The company is focused on securing its technologies globally, which is a defintely necessary step for any specialty pharmaceutical firm.

SciSparc Ltd. (SPRC) - Ansoff Matrix: Diversification

SciSparc Ltd. (SPRC) had a market capitalization of $2.77 million as of late 2025, with 1.62 million shares outstanding. The Price-to-Earnings (P/E) ratio (TTM) as of December 1, 2025, was -0.706.

The company reported a net loss of USD 0.5 million for the third quarter ending September 30, 2025, compared to a loss of USD 0.419 million a year ago. For the nine months ending September 30, 2025, the net loss was USD 1.46 million.

The following table summarizes key financial figures from recent periods for SciSparc Ltd. (SPRC).

The stock price saw a decrease of -62.16% over the last 52 weeks, closing at USD 1.840 on December 1, 2025.

Regarding potential diversification vectors, the following represent strategic areas:

• Apply the proprietary cannabinoid technology platform to the veterinary medicine market for companion animals.
• Acquire a complementary nutraceutical company with established distribution channels in the US.
• Develop a diagnostic tool or companion device to personalize dosing of their CNS drugs.
• Enter the oncology supportive care market with a new compound for chemotherapy-induced nausea.
• Establish a contract research organization (CRO) arm to monetize internal clinical trial expertise.

The company's 2024 Research and Development Expenses were $1,707 thousand. Sales, General and Admin Expenses for the same period were $4,771 thousand.

Recent corporate actions indicate movement toward diversification outside core CNS programs, such as entering the medical endoscopy systems market through a patent treasury acquisition announced November 26, 2025. The company also announced plans on November 14, 2025, to enter the GERD device market via an IP portfolio acquisition.

Financial structure metrics as of late 2025 include:

• Interest Coverage: -247.93.
• Revenue Per Employee: $653,000.
• Profits Per Employee: -$3.24M.